South Africa moves to substantive examination for pharma patents, amid fears system could grind to halt 15 Jun 18
Pharmaceutical patent owners may have been concerned to read some of the key features of South Africa’s new IP policy. Recently adopted by the country’s cabinet, it seeks to clamp down on perceived “evergreening” by life sciences companies – raising the prospect of changes to patentability criteria – and suggests an increased role for compulsory licensing.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
IAM explores how businesses can leverage IP rights as real assets beyond their traditional use. As the magazine addresses IP management issues without overly dwelling on legal matters, I consider it an eminently useful reference for innovative business executives.
Dr Frank Cuypers
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email